Adverse events after CAR T-cell infusion
| . | All patients (N = 81) . | With HSCT (N = 65) . | Without HSCT (N = 16) . | P value . | <5% blasts (N = 44) . | ≥5% blasts (N = 37) . | P value . | ELIANA (N = 75) . | P value . |
|---|---|---|---|---|---|---|---|---|---|
| CRS (1-5), n (%) | 55 (67.9) | 42 (64.6) | 13 (81.2) | .202 | 26 (59.1) | 29 (78.4) | .064 | 58 (77.3) | .188 |
| CRS (≥3), n (%) | 5 (6.2) | 4 (6.2) | 1 (6.2) | .989 | 0 (0.0) | 5 (13.5) | .012 | 35 (46.7) | <.001 |
| CRS (5), n (%) | 2 (2.5) | 2 (3.1) | 0 (0.0) | .477 | 0 (0.0) | 2 (5.4) | .118 | 0 (0.0) | .171 |
| ICANS (1-5), n (%) | 6 (7.4) | 5 (7.7) | 1 (6.2) | .844 | 2 (4.5) | 4 (10.8) | .283 | 30 (40.0) | <.001 |
| ICANS (≥3), n (%) | 4 (4.9) | 3 (4.6) | 1 (6.2) | .787 | 1 (2.3) | 3 (8.1) | .227 | 10 (13.3) | .067 |
| ICANS (5), n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA | 0 (0.0) | 0 (0.0) | NA | 0 (0.0) | NA |
| . | All patients (N = 81) . | With HSCT (N = 65) . | Without HSCT (N = 16) . | P value . | <5% blasts (N = 44) . | ≥5% blasts (N = 37) . | P value . | ELIANA (N = 75) . | P value . |
|---|---|---|---|---|---|---|---|---|---|
| CRS (1-5), n (%) | 55 (67.9) | 42 (64.6) | 13 (81.2) | .202 | 26 (59.1) | 29 (78.4) | .064 | 58 (77.3) | .188 |
| CRS (≥3), n (%) | 5 (6.2) | 4 (6.2) | 1 (6.2) | .989 | 0 (0.0) | 5 (13.5) | .012 | 35 (46.7) | <.001 |
| CRS (5), n (%) | 2 (2.5) | 2 (3.1) | 0 (0.0) | .477 | 0 (0.0) | 2 (5.4) | .118 | 0 (0.0) | .171 |
| ICANS (1-5), n (%) | 6 (7.4) | 5 (7.7) | 1 (6.2) | .844 | 2 (4.5) | 4 (10.8) | .283 | 30 (40.0) | <.001 |
| ICANS (≥3), n (%) | 4 (4.9) | 3 (4.6) | 1 (6.2) | .787 | 1 (2.3) | 3 (8.1) | .227 | 10 (13.3) | .067 |
| ICANS (5), n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA | 0 (0.0) | 0 (0.0) | NA | 0 (0.0) | NA |